Favipiravir

規格

259793-96-9CAS番号

856-840-0EC番号

5-fluoro-2-oxo-1H-pyrazine-3-carboxamideIUPAC名

C5H4FN3O2化学式

157.1 g/mol分子量

Favipiravir; 259793-96-9; avigan; 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE; T-705; 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; T 705; Fapilavir; Favilavir; T-705 cpd; EW5GL2X7E0; T705; 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-; CHEBI:134722; DTXSID60948878; favipiravirum; Avipiravir; RefChem:6434; J05AX27; DTXCID701377091; 856-840-0; 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide; Favipiravir (T-705); 2-Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-; Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-; 6-fluoro-3-hydroxy-pyrazine-2-carboxamide; Favipiravir; T-705; MFCD12032148; Favipiravir [INN]; UNII-EW5GL2X7E0; Favipiravir [USAN:INN:JAN]; 6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide; 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide; 6-Fluoro-3,4-dihydro-3-oxo-pyrazinecarboxamide; 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide; Favipiravir; T 705; T 705 (Pharmaceutical); Avigan (TN); Favipiravir/T-705; Favipiravir (Standard); FAVIPIRAVIR [MI]; FAVIPIRAVIR [JAN]; FAVIPIRAVIR [USAN]; Favipiravir (T-705)?; FAVIPIRAVIR [WHO-DD]; 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide; SCHEMBL587913; Favipiravir (JAN/USAN/INN); CHEMBL221722; orb1225488; orb1300424; SCHEMBL6378032; GTPL11139; ZCGNOVWYSGBHAU-UHFFFAOYSA-N; GLXC-04705; HMS5086M03; EX-A2285; EBC-06186; HY-14768R; MSK160867; s7975; AKOS005166863; AKOS015995178; CCG-266269; CS-0612; DB12466; FF29069; PB25591; PB42412; 6-Fluoro-3-hydropyrazine-2-carboxamide; NCGC00373041-03; NCGC00373041-05; NCGC00373041-06; AC-28900; DA-19682; HY-14768; MS-20791; SY110833; 6-fluoro-3-hydroxypyrazine-2-carbo xamide; NS00071016; D09537; EN300-1601539; F079875; T 705,CAS;259793-96-9; BRD-K04264130-001-01-4; Q16934561; Z1255381648別名